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ABSTRACT
Introduction. Immunohistochemical staining is currently the gold standard of diagnostic and classification 
of pituitary adenomas. However, there are some discrepancies between immunohistochemical staining 
results and the clinical picture of pituitary adenomas. Pituitary adenomas with positive immunohistochemical 
reaction might not cause any endocrinological symptoms or changes in serum pituitary hormone levels. 
Such a discordance may be caused partly by clinically non-functioning pituitary adenomas (CNFPAs). 
The aim of our study was to establish the frequency of CNFPAs and identify their histological types using 
quantitative immunohistochemical assessment. 
Materials and methods. We enrolled in the study 72 patients with pituitary adenoma, and their medical 
history was evaluated retrospectively. The immunohistochemical panel of anterior pituitary hormones was 
introduced in all cases. The immunoreactivity index was calculated manually for each specimen. 
Results. 36.1% patients of the evaluated group presented as CNFPAs. Among the CNFPA patients we 
found 38.46% cases with positive immunohistochemical reaction for one or more anterior pituitary lobe 
hormones. In 23.07% of cases the adenomas were monohormonal, and in 15.38% they were plurihormonal.
Conclusions. The morphometric method utilising the immunoexpression index introduced in this study 
provided a very precise recognition of pituitary adenoma pathology. In the case of CNFPAs the immuno-
histochemical staining often reveals a positive reaction also for multiple pituitary hormones. Quantitative 
assessment limits the subjectivity of the examiner and allows objective results comparison, so it should 
become a standard in histopathological assessment of pituitary adenomas.
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Introduction
Pituitary adenomas are benign neoplasms arising 
from anterior pituitary secretory cells [1]. They constitute 
10–20% of all intracranial neoplasms treated surgically 
and are the most common neoplastic lesion in the sellar 
region [2–4].
Due to their secretory activity, pituitary adenomas 
are divided into functioning and non-functioning 
types. Functioning adenomas manifest signs of endo-
crinopathies: galactorrhoea-amenorrhea syndrome [5], 
acromegaly or gigantism [6], Cushing disease [7], and 
secondary hyperthyroidism [8]. The non-functioning 
type, described as clinically non-functioning pituitary 
adenomas (CNFPAs), have no secretory activity and 
manifest when reaching large size [9]. They produce 
certain neurological symptoms such as: headache, 
bitemporal haemianopsia, impairment of vision acui-
ty, and eye movement abnormalities. In some cases, 
CNFPAs lead to hypopituitarism or stalk syndrome 
[4, 10–14].
Immunohistochemical staining is currently the gold 
standard of diagnosis and classification of pituitary ade-
nomas [3]. However, immunohistochemical results are 
not always consistent with the clinical picture. Pituitary 
adenomas with positive immunohistochemical reaction 
might not cause any endocrinological symptoms or 
changes in serum pituitary hormones levels [15–18]. 
In the case of CNFPAs, inconsistency between the lack 
of hormone hyperexpression symptoms and positive 
immunohistochemical reaction may be caused by low 
hormone synthesis or fast decay before secretion in 
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lysosomes of adenoma cells [9, 19, 20]. Another cause 
that should be mentioned is a  disorder of hormone 
storage or synthesis as well as release of biologically 
inactive hormones [21, 22]. The aim of our study was 
to establish the frequency of the CNFPA and identify 
their histological types using quantitative immunohis-
tochemical assessment. 
Materials and methods
We enrolled to our study patients operated on in the 
Department of Neurosurgery and Neurotraumatology 
of Jagiellonian University Medical College in Krakow 
and diagnosed in the Department of Neuropathology. 
The final study group consisted of 72 patients with 
complete clinical, histopathological, and radiological 
documentation. Demographic characteristics of study 
group are presented in Table 1. We collected patients’ 
detailed medical records including medical history, neu-
rological condition, co-morbidities, current medications, 
results of neurological and general examination, and, 
in particular, endocrinological symptoms and details 
about surgical procedures. Patients’ endocrinological 
diagnoses are presented in Figure 1. All patients had 
full immunohistochemical panel for anterior pituitary 
lobe hormones: prolactin (PRL), growth hormone (GH), 
adrenocorticotropic hormone (ACTH), thyroid-stimulat-
ing hormone (TSH), luteinising hormone (LH), follicle 
stimulating hormone (FSH), and alpha-subunit (a-SU). 
We compared every specimen with stained specimens 
from control autopsy samples to confirm that they were 
stained properly. A short specification of each hormone 
staining is presented in Table 2. 
We examined all sections using a light microscope 
(Nikon Optishot-2) under magnification of 200x and 
400x. We ruled out all parts of specimens without ade-
noma tissue, where we found pituitary tissue, fibrosis, 
haemorrhage, etc. We proceeded to morphometric 
analysis if at least one visual field under 200x magnifi-
cation included adenoma tissue without mechanical or 
thermic damage and massive necrotic or haemorrhagic 
lesions. If we were unable to assess the specimen, we 
collected another sample and repeated staining. 
To assess hormonal expression we used cell 
indexes; under 400x magnification we calculated the 
percentage of cells with positive immunohistochemical 
reaction. To perform morphometric analysis we used 
a morphometric grid (Fig. 2) consisting of 16 areas 
with equal surfaces. In each area we calculated the 
number of positively stained cells and number of all 
visible cells. 
Table 1. Demographic characteristic
Gender n % Age (years)
Average SD Min Max
Female 44 61.11 45.1 19.1 10 84
Male 28 38.89 49.9 16.7 23 75
Together 72 100.00 46.9 18.2 10 84
Cnfpa* 
Akromegaly 
Cushing disease 
Hiperprolactinemia 
Hiperthyreosis 
Precocious puberty
50%45%40%35%30%25%20%15%10%5%0%
9.7% (n = 7) 
18.1% (n = 13) 
1.4% (n = 1) 
1.4% (n = 1) 
33.3% (n = 24)
36.1% (n = 26)
Figure 1. Endocrinological diagnoses. CNFPAs — clinically non-functioning pituitary adenomas
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Table 2. Methods of immunohistochemical staining
Antibody Producer Dilution Incubation time Visualisation  
of reaction
Comments
Anti-PRL Dako,  
Denmark
Ready  
to use
15 minutes, room 
temperature
EnVISION TM+ System Labelled 
Polymer HRP-ant rabbit
Anti-GH Dako,  
Denmark
Ready  
to use
15 minutes, room 
temperature
EnVISION TM+ System Labelled 
Polymer HRP-anti-rabbit
Anti-ACTH Dako,  
Denmark
Ready  
to use
15 minutes, room 
temperature
EnVISION TM+ System Labelled 
Polymer HRP-anti-rabbit
Anti-TSH Novocastra,  
Great Britain
01:25 24 h 4 °C ABC KIT Vectastain Universal Antigen unmasking by 2 × 5 
min in pH = 6.0 buffer
Anti-LH
Anti-FSH
Dako,  
Denmark
01:25 30 minutes, room 
temperature
EnVISION TM+ System Labelled 
Polymer HRP-ant mouse
Antigen unmasking by 2 × 5 
min in pH = 6.0 buffer
Anti-a-SU Novocastra,  
Great Britain
0,100 24 h 4°C ABC KIT Vectastain Universal Antigen unmasking by 2 × 5 
min in pH = 6.0 buffer
Figure 2. Morphometric grid
The small number of the IHCH-positive cells on cir-
cuit of adenoma were recognised as “trapped” proper 
cells of adenohypophysis and was not counted. For 
each haematoxylin and eosin stained specimen we cal-
culated the surface area. This analysis was performed 
for five reliable parts of each specimen.
This study was conducted in accordance with 
the ethical standards laid down in the Declaration of 
Helsinki (1964) and its design was approved by the 
local University Ethical Committee (protocol number 
KBET/157/B/2012).
Results
Final study group consisted of 72 patients between 
10 and 84 years of age (mean age was 46.9 years); 
44 (61.11%) of them were females. We examined a total 
of 504 specimens in light microscope for assessment 
of tropic hormones and a-SU. Eighty-four of them 
were considered as positive. Immunohistochemical 
reactions were positive for 43 patients. We diagnosed 
22 monohormonal adenomas (30.56%), 21 plurihor-
monal adenomas (29.17%), and 21 hormonally negative 
adenomas (29.17%). We were unable to interpret immu-
nohistochemical reactions in eight cases (11.11%), and 
we considered them as unreliable. Among the 26 cases 
with CNFPA, we found negative immunohistochemical 
reaction in 14 (53.85%). In 10 (38.46%) cases we found 
positive immunohistochemical reaction for anterior 
pituitary lobe hormones — six of them were monohor-
monal, and four were plurihormonal. Two patients had 
unreliable reactions. The number and type of positive 
reactions among patients with CNFPA are presented in 
Table 3. The exact profiles of plurihormonal adenomas 
are listed in Table 4.
Table 3. Positive immunohistochemical reactions among 
patients with CNFPAs
Reactions Count Percentage 
immunoexpression
Anti-PRL 0 –
Anti-GH 0 –
Anti-ACTH 2 16.9%, 41.3%
Anti-TSH 1 12%
Anti-LH 3 15.4%, 34.6%, 44%
Anti-FSH 3 19.1%, 52.3%, 69.7%
Anti-a-SU 6 14.6%, 17.9%, 27.1%, 44.1%, 
44.6%, 70%
Together/average 15 34.9%
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Table 4. Plurihormonal adenomas among the CNFPAs
Anti-PRL Anti-GH Anti-ACTH Anti-TSH Anti-FSH Anti-LH Anti-a-SU
– 17% 8% – 53% – 24%
– – – – 52.3% 44.9% 41.1%
– – – – – 15.4% 44.6%
– – – 7.1% – – 87.5%
Discussion
The distinction of the CNFPA is crucial for differential 
diagnosis. Lack of secretory activity means that clinical 
manifestation of the CNFPA is mainly connected with 
neurological symptoms of mass effect, similarly to other 
tumours in sellar and parasellar location (meningioma, 
craniopharyngioma) [23, 24].
The CFNPAs constituted 36.11% of the entire mate-
rial. Their frequency in literature varies between 25 and 
30% [9, 22]. Knosp et al. in their research established it 
as 46% [25]. Among the CNFPAs 38.46% had positive 
immunohistochemical reactions. Occurrence of the 
CFNPAs with positive reaction is very diverse in literature 
and varies between 21.2% and 87% [14, 22, 26]. In Kno-
sp et al.’s research it was established as 15.78% [27]. 
This is partially explained by the electron microscopy 
study, which showed the existence of secretory grains 
in CFNPAs cells [28].
The fact that the immunohistochemically positive 
adenomas do not reflect clinical image can be explain 
by several different theories. Adenomas can secrete 
hormones in a concentration that is not high enough 
to cause a clinical effect [13]. Also, the produced hor-
mone might be biologically inactive or might decay in 
lysosomes [28].
Most of the CNFPAs produce gonadotropins or 
glycoprotein hormone subunits [22]. We found six 
positive reactions for gonadotropins and six positive 
reactions for a-SU. 
The CNFPAs are a heterogeneous group consist-
ing of null cell adenomas, oncocytic adenomas, silent 
somatotroph adenomas, silent corticotroph adenomas, 
silent thyrotroph adenomas, and silent gonadotroph 
adenomas [9]. Elevated LH and FSH serum levels are 
present in 25% of the CFNPAs, but do not correlate with 
LH and FSH immunoexpression [14]. In our research 
we found no changes in serum level of gonadotropins 
in patients with CNFPAs. 
Among the CNFPAs with positive reactions we found 
four cases of plurihormonal adenomas. Those results 
are also consistent with a lack of correlation between 
clinical image and neuropathological assessment. 
Adenomas with expression of more than one hormone 
can be clinically silent [2, 29].
All of the hormonally negative adenomas were mac-
roadenomas, which is consistent with other research-
ers’ studies. Saeger et al. found that 95–100% of the 
CNFPAs are macroadenomas, and most of them show 
no hormonal expression in immunohistochemical exam-
inations [14]. That phenomenon is probably caused by 
the fact that those tumours were able to grow silently 
until they caused visual symptoms [24].
The lack of full consistency between clinical and 
immunohistochemical images mostly concerns the 
CNFPAs, plurihormonal adenomas, and unreliable spec-
imens. The CNFPAs qualified to a surgical treatment are 
usually large tumours with suprasellar growth. Morpho-
metric immunohistochemical assessment with immuno-
reactivity index allows very accurate assessment of the 
CNFPAs hormonal expression. Those methods limit the 
subjectivity of the examiner and allow objective compar-
ison of results; therefore, it should become a standard 
in histopathological assessment of pituitary adenomas.
Conflict of interest: None declared.
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